Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Be6A Lung-01: Sigvotatug Vedotin versus docetaxel in previously treated non-squamous NSCLC
CTR20244723Phase 3Active
- Sponsor
- Seagen Inc.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sigvotatug vedotin in non-small cell lung cancer (NSCLC), sponsored by Seagen Inc.. Started Mar 2025; status: active.
02
Drugs
sigvotatug vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244723.